RE:Ceapro / Aeterna Merger Assurances"I kept telling Gilles for years that his barometer was the stock price, he never agreed."
We will have a much better benchmark for what all of this is worth once key valuation milestones are hit and reported. This company is still pretty much top secret at this point and in stealth mode. It is very hard for the market to value the avenanthramide pill when it has been given zero preclinical or clinical data for the pill formulation. The Phase I/IIa clinical trial will provide safety/tolerability and preliminary efficacy data in humans. It will have a proof of principle in humans. The company has previously talked about partnering with this proof of principle in hand which can further provide key validation to the market. Given the merger has now optimized the company to bring "transformational" products to market, according to Ronnie Miller, maybe they see something special happening and are positioned to add even greater value. The wound healing data is interesting for avenanthramide.
PGX is currently only proven to a 10L pilot facility that you can't do anything commercial with. It is a burnrate with a risky timeline to market. By the end of this year the 10L pilot facility could be derisked to 5X and 10X. PGX could have its first Health Canada approved product available commercially and be generating revenue. PGX could be proven to the decision-point for mass industrialization(100L). As opposed to needing a 100X scale-up it would only need a 10X further scale up to 1000L and would have just completed a 10X scale-up to 100L. A partnership could further validate the technology providing key information to the market. Last November the company also said that it had designed an animal trial protocol for the immune booster. During the 2023 AGM Gilles said they were talking with serious potential partners about PGX. With the merger closed interesitng deals could result.
PGX-YBG/fibrosis is currently undergoing peer-review at an influencial scientific journal(Biomaterials). It is a comprehensive article detailing what they've discovered.
The wound healing data looks very interesting. Healing wounds in half the time and without scaring would appear a breakthough. Gilles called it a home run previously and Dr. William Li appears genuinely excited; including after discussing the results at a medical conference.
The pediatric data for the diagnostic and a licensing deal will be key events. Gilles was on the Board of AEZS and so is positioned to know what we can't currently concerning the interest in this test. Other assets of AEZS are also being evaluated.
This is highly risky stuff but they wanted a NASDAQ listing. The merger is now complete. The name has been changed along with the symbol. The new plan is about to be revealed.
“We are very pleased with the ongoing post-merger integration process and expect to be providing a fulsome update shortly." Aug. 13, 2024
Ronald W. Miller, Chair of the Company: “With the successful completion of this merger, we are now optimized to bring value-driving, transformational products to the market.” June 3, 2024